Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity. - Wikidata - awgldk - TriplyDB

Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity.

Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity.

http://www.wikidata.org/entity/Q46202438

about

CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians Warfarin therapy: in need of improvement after all these years.Risk factors for nonadherence to warfarin: results from the IN-RANGE study.Patient attitudinal and behavioral factors associated with warfarin non-adherence at outpatient anticoagulation clinics.Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans.Genotype and risk of major bleeding during warfarin treatment.Genetic warfarin dosing: tables versus algorithms.The use of vitamin K supplementation to achieve INR stability: a systematic review and meta-analysis.Factors affecting time to maintenance dose in patients initiating warfarin.Pharmacogenomics of warfarin in populations of African descent.Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans Use of genetic and nongenetic factors in warfarin dosing algorithms.Comparative evaluation of warfarin utilisation in two primary healthcare clinics in the Cape Town area Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics.Influence of CYP2C9 Genotype on warfarin dose among African American and European Americans.Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.Warfarin sensitivity genotyping: a review of the literature and summary of patient experience.Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.Clinical applications of pharmacogenomics guided warfarin dosing.Performance outcomes of a pharmacist-managed anticoagulation clinic in the rural, resource-constrained setting of Eldoret, Kenya.Predicting prolonged dose titration in patients starting warfarin.New genetic variant that might improve warfarin dose prediction in African Americans.Genetic analysis to prevent warfarin complications.Search for the molecular basis of ultra-rapid CYP2C9-catalysed metabolism: relationship between SNP IVS8-109A>T and the losartan metabolism phenotype in Swedes.Factors influencing warfarin dose requirements in African-Americans.An assessment of the impact of pharmacogenomics on health disparities: a systematic literature review.Influence of Kidney Transplant Status on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage.

P2860

Q24641999-1B0E027D-11B7-48A1-BACA-64FFD5DDB546 Q27002899-F955D1D2-8D0D-4BA3-BCBD-1CD962B586E6 Q31016306-8F384000-4C0A-44F9-85BD-2E98DCFAC0A3 Q33793086-427A4A16-B866-4FB0-A7C2-FB3D0A039655 Q34056085-97178E37-A63E-473E-9C80-585F02D73FD5 Q34056113-E157592D-03B3-4408-B4FC-B843036D6137 Q34284362-0CBA6A3E-A7D4-4CE2-AC7D-ECAD1EC3F0C9 Q35006973-9A955260-37CE-40E0-8C42-5148CFDB3A00 Q35021027-13D4D39B-100E-42F7-AC33-D306CCCC25E5 Q35028466-39F523C9-5767-4DAD-B4C0-40EFD9566DBB Q36060109-66D67C0B-43C7-4B83-B57C-F7C023A07DB4 Q36629209-67508542-6CA6-492C-A8B0-36B16319C93F Q36882317-73D5F701-65FB-49CA-BF89-5FB61F1C13FA Q36982736-C7E09236-1A04-4ECE-BDC1-1EA6113541F5 Q37074097-27C58AB5-2642-4624-96E7-A84A9AC6BC9A Q37077528-21E562BA-0EBD-4D6D-A843-56B5C3F9285E Q37264555-F132A133-1467-480B-8957-14AA9C8930F4 Q37372721-ABD788D7-A17B-43D4-9891-836D7E219EFF Q37376879-05097EA3-E651-4E06-8003-140BDC9AC202 Q37454438-CA1D74B2-CC06-4A9A-9171-5895648B6F33 Q37463152-24FFACD6-D516-4974-9AC0-D181AAFDFD4C Q37807280-6069FF53-EBAE-4B36-91C7-6D191341CC10 Q37931395-64BC20D5-C8FB-40A1-8E11-343AF6CF3EDA Q39561868-D8A1AF5E-3F66-453F-B82C-706B43934DC7 Q39846791-24C6F11B-020E-448A-B82F-4F02D4CA28AE Q42424928-98078FC5-2E4C-4455-8CC1-7399126F04A1 Q45094170-6340DAD1-6DFE-4811-9F19-8925AB3B5F0F Q46885448-A3886AFD-5256-467E-9804-5D43B57880B1 Q47622750-CE92D6C7-5B23-4BF7-8C77-7D92BD1B5E55 Q47920228-FFBEEEA8-356F-4AE1-B0DB-C80A1F12AB27

P2860

Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity.

http://www.wikidata.org/entity/Q46202438

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Warfarin and cytochrome P450 2 ...... ation in warfarin sensitivity.

@en

Warfarin and cytochrome P450 2 ...... ation in warfarin sensitivity.

@nl

type

label

Warfarin and cytochrome P450 2 ...... ation in warfarin sensitivity.

@en

Warfarin and cytochrome P450 2 ...... ation in warfarin sensitivity.

@nl

prefLabel

Warfarin and cytochrome P450 2 ...... ation in warfarin sensitivity.

@en

Warfarin and cytochrome P450 2 ...... ation in warfarin sensitivity.

@nl

P1433

Q46202438-9F271BDA-8C2D-4640-86E2-509EE22C7E09

P1476

Q46202438-2F11B8E9-CD0D-4F30-B1E0-4427C5847EE0

P2093

Q46202438-1067AD5B-F614-489A-98B1-AD760FFF6158

Q46202438-1C6D4D4D-4854-46D8-B8F2-C634392A2DBF

Q46202438-5F53D479-8F72-491F-A4AB-B548579CBA11

Q46202438-81A6A626-F0E1-4D62-A5E6-C55A01FB1384

Q46202438-8FD45F96-5298-4D79-8100-4E9557F51D18

Q46202438-A4FF1D97-DAEE-45F8-A09D-998558867A35

Q46202438-F5CA9606-20F8-45B8-A4F9-6B8BB8CFA369

P2860

Q46202438-0698D9C4-1D45-4958-A869-820303263E6F

Q46202438-19F496C4-41AB-4D49-8E10-44D4C77C28F3

Q46202438-462ACBF7-4150-44F4-8270-8C6B03F22F42

Q46202438-4D42CEF9-35AE-4A02-A207-5DC80B19C8C1

Q46202438-53E5BF1E-0C27-4B22-84EB-19C01C547731

Q46202438-5B7FC5C5-2251-4CEA-B116-477BB9FB9CDB

Q46202438-6156A2BB-2DC0-4129-8F88-C7ED19523C0D

Q46202438-72AE2A21-9457-4D46-915C-DF5288A1D745

Q46202438-9E70FE1D-D27A-4D71-9F2A-DF5DADDE4C63

Q46202438-AD429792-FE47-4727-951C-AAE986E97A23

P304

Q46202438-3802A48F-D21D-4531-8D4B-A18EF849BCA4

P31

Q46202438-B4F5040D-5345-4602-866A-437665EE85B1

P356

Q46202438-31425129-55CA-409E-9359-A9D0FBC55CBF

P433

Q46202438-3809D9E4-60E6-421F-B85E-A247102DC19A

P478

Q46202438-2C1A266D-830E-4B03-BA33-6EA2A42B07BF

P50

Q46202438-A7CD9E5E-48AB-4F4B-B4D6-9275815F8E04

P577

Q46202438-7B263103-92A3-482D-8FF9-C104298A1378

P698

Q46202438-6F00567C-F695-4554-8835-B01CF570DDFD

P356

14622416.8.3.217

P1433

Pharmacogenomics

P1476

Warfarin and cytochrome P450 2 ...... ation in warfarin sensitivity.

@en

P2093

Alexander S Whitehead

http://www.w3.org/2001/XMLSchema#string

Carmel Kealey

http://www.w3.org/2001/XMLSchema#string

Caroline F Thorn

http://www.w3.org/2001/XMLSchema#string

Frederick F Samaha

http://www.w3.org/2001/XMLSchema#string

Jason Christie

http://www.w3.org/2001/XMLSchema#string

Maureen Price

http://www.w3.org/2001/XMLSchema#string

Stephen E Kimmel

http://www.w3.org/2001/XMLSchema#string

P2860

Managing oral anticoagulant therapy.

Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety.

Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.

Genetic polymorphisms in assessing interindividual variability in delivered dose.

Management of haemorrhagic complications associated with oral anticoagulant treatment.

Clinical consequences of cytochrome P450 2C9 polymorphisms.

Human P450 metabolism of warfarin.

The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin.

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.

P304

217-225

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/14622416.8.3.217

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17324110

http://www.w3.org/2001/XMLSchema#string